Spyre Therapeutics (SYRE) R&D In Process (2023)
Spyre Therapeutics (SYRE) has disclosed R&D In Process for 1 consecutive years, with -$298000.0 as the latest value for Q3 2023.
- For the quarter ending Q3 2023, R&D In Process changed N/A year-over-year to -$298000.0, compared with a TTM value of -$298000.0 through Dec 2024, down 100.23%, and an annual FY2023 reading of $130.2 million, changed N/A over the prior year.
- R&D In Process was -$298000.0 for Q3 2023 at Spyre Therapeutics, down from $130.5 million in the prior quarter.
- Across five years, R&D In Process topped out at $130.5 million in Q2 2023 and bottomed at -$298000.0 in Q3 2023.